Akebia Therapeutics, Inc. (AKBA) vs Organigram Global Inc. (OGI)
- Akebia Therapeutics, Inc. AKBA 0.67 −4.29%
- Organigram Global Inc. OGI 0.93 0.00%
Akebia Therapeutics, Inc. and Organigram Global Inc. are both Drug Manufacturers Specialty & Generic companies. Akebia Therapeutics, Inc. is the larger, with a market value of $192.7M against $131.4M — 1.5× the size. Akebia Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Organigram Global Inc. trades at 2.0×. Organigram Global Inc. grew revenue faster over the last twelve months: 39.5% against 7.52%. Organigram Global Inc. has the higher net margin (28.4% vs −13.5%) and the lower return on invested capital (−1.53% vs 0.00%). Across the 18 metrics below, Organigram Global Inc. leads on 12 and Akebia Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | AKBA | OGI | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 79.63% | 36.47% | 53.94% |
| Operating margin | (6.90%) | (3.91%) | 0.00% |
| Net margin | (13.54%) | 28.44% | 0.00% |
| Free cash flow margin | 18.38% | (9.46%) | 0.00% |
| Return on equity | (109.38%) | 20.20% | (0.40%) |
| Return on assets | (8.53%) | 12.70% | (3.32%) |
| Return on invested capital | 0.00% | (1.53%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack